Articles On Neuren Pharmaceuticals (ASX:NEU)

Highlights Market sentiment remains cautious as sector leadership rotates Defensive assets attract attention amid uneven trading conditions Select ASX-listed names experience heightened activity Australian equities are...

The Lynas Rare Earths Ltd (ASX: LYC) share price has seen massive volatility over the last year. In the past 12 months, it's up by almost 90%, as the chart below shows. That compares to a rise of less than 5% for the S&P/ASX 200 Index (...

It was a rough start to the trading week for the S&P/ASX 200 Index (ASX: XJO) and many ASX shares this Monday. After ending the week on a distinct high last Friday, investors were a little less enthused...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a disappointing decline. At the time of writing, the benchmark index is down 0.8% to 8,629.6 points. Four ASX shares that are not letting that hold them back to...

Highlights Market-wide weakness reshapes sector leadership Select defence, healthcare and mining names regain attention Policy shifts and governance reforms redraw expectations Australian shares softened as global sent...

Neuren Pharmaceuticals Ltd (ASX: NEU) shares are starting the week strongly. In morning trade, the ASX 200 stock is up 3.5% to $19.59. Why is this ASX 200 stock rising today? Investors have been bidding the pharmaceuticals company's shares...

The Westgold Resources Ltd (ASX: WGX) share price is in focus after the company announced plans to spin out its non-core Reedy and Comet gold projects into a new standalone vehicle, Valiant Gold Limited, with an associated IPO in Q3 FY26. K...

The IperionX Ltd (ASX: IPX) share price is in focus today after the company announced a new project with Carver Pump to accelerate the production of critical titanium components for U.S. Navy ships. The initial purchase order includes proto...

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is making headlines today after announcing US FDA approval for DAYBUE STIX, a new powder formulation of trofinetide for Rett syndrome. This milestone gives patients and caregivers more f...

The Fortescue Ltd (ASX: FMG) share price is in focus after announcing its plan to acquire the remaining 64% of Alta Copper Corp for C$139 million, offering shareholders a 50% premium to Alta Copper's recent 30-day VWAP. This strategic move...

Junior biotechnology company Echo IQ Ltd (ASX: EIQ) has lodged a key submission with the US Food & Drug Administration (FDA), which will help pave the way for sales of its heart failure detection software. The artificial intelligence...

The DigiCo Infrastructure REIT (ASX: DGT) share price is in focus today after the company declared a 1H FY26 distribution of 6.0 cents per security, rewarding investors and highlighting progress on its data centre growth plans. What did Dig...

The Treasury Wine Estates Ltd (ASX: TWE) share price was placed in a trading halt today as the company prepares to release a significant announcement and host an investor update session, which will cover its outlook. What did Treasury Wine...

The ASX small-cap stock Kelsian Group Ltd (ASX: KLS) has the potential to deliver very pleasing returns to investors, and I think it's a solid buy for the long-term. The fact that its share price has slipped 18% since 7 October 2025 make...

It was a tough Tuesday for the S&P/ASX 200 Index (ASX: XJO) and many ASX shares today. After a bouncy day, the ASX 200 ended up closing 0.45% lower, probably unassisted by the Reserve Bank of Australia'...

A global study links Alzheimer’s disease with kidney malfunction FDA czar Dr Marty Makary outlines the agency’s priorities Pro Medicus fesses up to a cyber breach   The quest for an Alzheimer’s disease cure has taken a new twist, with an...

Strong clinical data can help biotechs secure lucrative licensing and partnership deals  Dimerix has four licensing deals for lead drug DMX-200 in rare kidney disease Platinum’s Global Health Sciences Fund manager Dr Bianca Ogden notes se...

The S&P/ASX 200 Index (ASX: XJO) ended the trading week on a very hard note indeed, suffering a nasty drop this Friday. By the time trading wrapped up today, the ASX 200 had tumbled a notable 1.36%. T...

Investors in Neuren Pharmaceuticals Ltd (ASX: NEU) have experienced an exhilarating year. The ASX 200 healthcare stock has exploded with over 115% since hitting a 52-week low in April. Stock tipped to rise Analysts at Macquarie Group...

Two dozen esteemed sector figures recently gathered over lunch to recount their career highs and lows One luminary recalls an uncomfortable close encounter with a drug cartel, while others overcame the impact of academic and corporate frau...

It was a sour end to the trading week this Friday, as investors couldn't quite hold onto the optimism that we saw yesterday. By the close of trading, the S&P/ASX 200 Index (ASX: XJO) had sunk by a heft...

ASX health sector down 0.94% for past week, while broader market falls 1.22% Under pressure CSL moves to reassure investors at US Capital Markets Day this week Imricor soars after world’s first VT ablation performed entirely under real-tim...

It has been another busy week for many of Australia's top brokers. This has led to the release of a number of broker notes. Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these...

On Thursday, Neuren Pharmaceuticals Ltd (ASX: NEU) shares were sold off and finished the day 10% lower. While this is disappointing for shareholders, the team at Bell Potter thinks that it has created an attractive entry point for investors...

Yesterday afternoon, ASX 200 company GPT Group (ASX: GPT) upgraded its 2025 full-year guidance, buoyed by a strong September quarter. Retail investment portfolio occupancy hit 99.6%, while group-wide weighted average lease expiry (WALE) sto...

The James Hardie Industries (ASX: JHX) share price has come under pressure today, sliding from $29.48 yesterday to a low of $24.41 following a notable spike in trading volume. What did James Hardie Industries report? The JHX share price fe...

Australian biotechs are carving out expanded territory in the US Truscreen edges towards cash flow break even CSL is extracting more blood from donors, more efficiently   Today’s crop of ASX announcements highlights the potential of the U...

With more than seven million users on the HotCopper forums, every discussion and speculation can move Australian markets, which is why getting out in front of those trends is so important for any trader worth their salt. Listen to the Ho...

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is in focus today after the company reported record Q3 2025 DAYBUE net sales of US$101.1 million, up 11% from a year earlier, and royalty income of A$16.4 million, up 24% year-on-year. W...

The Vicinity Centres (ASX: VCX) share price is in focus today after the company reported statutory net profit of $1.0 billion for FY25—up from $547.1 million last year. Funds From Operations reached $674 million, with annual distribution...

The Growthpoint Properties Australia (ASX: GOZ) share price is in focus after the REIT delivered strong office and industrial leasing in the first quarter of FY26, with high portfolio occupancy and reaffirmed earnings guidance. What did Gro...

Buying or selling a used car can be a fraught process for the consumer. How do you know you're getting a good price? Is the car itself in good shape, or have you bought yourself a lemon that will cause you untold grief? The folks at Car...

The Amcor CDI (ASX: AMC) share price is in focus today after the global packaging leader unveiled first quarter FY26 results, including a 68% lift in net sales to US$5.75 billion and an 18% jump in adjusted earnings per share. What did Amco...

The Light & Wonder Inc (ASX: LNW) share price is in focus today after the gaming technology company reported third quarter net income jumping 78% to $114 million and consolidated revenue up 3% to $841 million. What did Light & Wond...

The Global X US 100 ETF Fund (ASX: U100) is an ASX ETF focused on innovation. This week, a report from the ETF provider shed light on the success of the fund since it adjusted its methodology.  Since September 2024, this ASX ETF...

The National Australia Bank Ltd (ASX: NAB) share price is in focus today after the bank posted a steady full-year result, with FY25 cash earnings coming in at $7,091 million and the dividend rising slightly to 232 cents per share. What did...

ASX healthcare sector fell 4.83% in October and is down more than 19% YTD CSL shares fall more than 15% on October 28 after management trims FY26 guidance Nyrada surges 165% in October on board changes and progress in phase 2a trial    Wi...

Broker Bell Potter has issued a new report on ASX healthcare stock Neuren Pharmaceuticals Ltd (ASX: NEU). It has maintained its buy rating and also increased its target price.  Neuren Pharmaceuticals is a biopharmaceutical company sp...

Jump back to 2021 and Neuren Pharmaceuticals Ltd (ASX: NEU) share price consistently traded around $1.50 and occasionally breached $2. Within three years it would hit a high of $25 a share. NEU received FDA approval for a drug called Trofen...

The Judo Capital Holdings Ltd (ASX: JDO) share price is in focus as the company delivered strong lending growth of 16% to $12.5 billion and increased underlying profit before tax by 14% to $125.6 million for FY25. What did Judo Capital Hold...

The Stanmore Resources Ltd (ASX: SMR) share price is in focus today after the company reported record quarterly run-of-mine (ROM) and saleable coal production at its South Walker Creek operation, alongside an improvement in net debt over th...

On Monday, the S&P/ASX 200 Index (ASX: XJO) started the week with a decent gain. The benchmark index rose 0.4% to 9,031.9 points. Will the market be able to build on this on Tuesday? Here are five things to watch: ASX 200 expected to...

Shareholders in Neuren Pharmaceuticals Ltd (ASX: NEU) are rejoicing after one of the company's drugs, which shows promise in treating a rare genetic disorder, received fast-track designation from the US Food & Drug Administration (FDA)....

The S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a small decline. In afternoon trade, the benchmark index is down slightly to 8,995.1 points. Four ASX shares that are not letting that hold them back are listed belo...

The Mesoblast Ltd (ASX: MSB) share price is in focus today after the company announced a 69% quarter-on-quarter increase in net revenues from its lead product Ryoncil®, reaching US$20.6 million for the September quarter. Cash on hand also...

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is in focus today after the company revealed that the US FDA has granted Fast Track designation for its NNZ-2591 treatment in Phelan-McDermid syndrome (PMS). This marks a significant mil...

Highlights Gold and critical minerals lead midday momentum across large, mid, and small names Defensive infrastructure and logistics display steady relative strength Technology, healthcare, and consumer brands face pressure...

PainChek can now tackle the US$100 million US aged-care market – while other geographies beckon Trivarx shares leap 9% on depression detection trial results Dimerix gets more assurances on using surrogate endpoints in its pivotal kidney t...

US FDA grants Rare Paediatric Disease Designation for Neurotech’s NTI164 for treatment of Rett syndrome Designation helps facilitate innovative treatments for rare paediatric diseases with enhanced regulatory support and potential priorit...

ALS Ltd (ASX: ALQ) is an ASX industrials stock that has already flown 40% higher in 2025.  In fact, it has repeatedly hit all-time highs this year.  It recently gained attention from a leading fund manager in the last couple of months...